Читать книгу Graves' Orbitopathy - Группа авторов - Страница 43
References
Оглавление1 Perros P, Dayan CR, Dickinson AJ, Ezra D, Estcourt S, Foley P, et al: Management of patients with Graves’ orbitopathy: initial assessment, management outside specialised centres and referral pathways. Clin Med (Lond) 2015;15:173–178.
2 Perros P, Zarkovic M, Azzolini C, Ayvaz G, Baldeschi L, Bartalena L, et al: PREGO (Presentation of Graves’ Orbitopathy) study: changes in referral patterns to European Group on Graves’ Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. Br J Ophthalmol 2015;99:1531–1535.
3 Bartley GB, Fatourechi V, Kadmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA: Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284–290.
4 Dickinson AJ, Perros P: Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001;55:283–303.
5 Kendler DL, Lippa J, Rootman J: The initial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol 1993;111:197–201.
6 Saks ND, Burnstine MA, Putterman AM: Glabellar rhytids in thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg 2001;17:91–95.
7 Velasco e Cruz AA, Vagner de Oliveira M: The effect of Müllerectomy on Kocher sign. Ophthal Plast Reconstr Surg 2001;17:309–315; discussion 315–316.
8 Koornneef L: Eyelid and orbital fascial attachments and their clinical significance. Eye 1988;2:130–143.
9 Frueh BR, Musch DC, Garber FW: Lid retraction and levator aponeurosis defects in Graves’ eye disease. Ophthalmic Surg 1986;17:216–220.
10 Gilbard JP, Farris RL: Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh) 1986;61:108–116.
11 Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R: Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639–644.
12 Khan JA, Donne JF, Whitacre MM: Does decompression diminish the discomfort of severe dysthyroid orbitopathy? Ophthal Plast Reconstr Surg 1995;11:109–112.
13 McKeag D, Lane C, Lazarus JH, Baldeschi L, Boboridis K, Dickinson AJ, et al: Clinical features of dysthyroid optic neuropathy: a European Group on Graves’ Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007;91:455–458.
14 Rubin PA, Watkins LM, Rumelt S, Sutula FC, Dallow RI: Orbital computed tomographic characteristics of globe subluxation in thyroid orbitopathy. Ophthalmology 1998;105:2061–2064.
15 Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477–588.
16 Peacy SR, Belchetz PE: Graves’ disease: associated ocular myasthenia gravis and a thymic cyst. J R Soc Med 1993;86:297–298.
17 Vaidya B, Cakes EJC, Imrie H, Dickinson AJ, Perros P, Kendall-Taylor P, Pearce SH: CTLA4 gene and Graves’ disease: association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin Endocrinol 2003;58:732–735.
18 Tellez M, Cooper J, Edmonds C: Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin. Clin Endocrinol (Oxf) 1992;36:291–294.
19 De Juan E, Hurley DP, Sapira JD: Racial differences in normal values of exophthalmos. Arch Intern Med 1980;140:1230–1231.
20 Tsai CC, Kau HC, Kao SC, Hou WM: Exophthalmos of patients with Graves’ disease in Chinese of Taiwan. Eye (Lond) 2006;20:569–573.
21 Perros P, Crombie AL, Matthews JNS, Kendall-Taylor P: Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993;38:367–372.
22 Krassas GE, Gogakos A: Thyroid-associated ophthalmopathy in juvenile Graves’ disease – clinical, endocrine and therapeutic aspects. J Pediatr Endocrinol Metab 2006;19:1193–1206.
23 Krassas GE, Segni M, Wiersinga WM: Childhood Graves’ ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005;153:515–521.
24 Durairaj VD, Bartley GB, Garrity JA: Clinical features and treatment of Graves’ ophthalmopathy in pediatric patients. Ophthal Plast Reconstr Surg 2006;22:7–12.
25 Young LA: Dysthyroid ophthalmopathy in children. J Pediatr Endocrinol Metab 1979;16:105–107.
26 Mourits MP, Ross GE, Garrity JA, Nardi M, Matton G, Koorneef L: Surgical management of Graves’ ophthalmopathy; in Prummel M (ed): Recent Developments in Graves’ Ophthalmopathy. London, Kluwer Academic Publishers, 2000, pp 133–169.
27 Neigel JM, Rootman J, Belkin RI, Nugent RA, Drance SM, Beattie CW, et al: Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 1988;95:1515–1521.
28 Trobe JD, Glaser JS, Laflamme P: Dysthyroid optic neuropathy. Clinical profile and rationale for management. Arch Ophthalmol 1978;96:1199–1209.
29 Soroudi AE, Goldberg RA, McCann JD: Prevalence of asymmetric exophthalmos in Graves’ orbitopathy. Ophthal Plast Reconstr Surg 2004;20:224–225.
30 Otto AJ, Koornneef L, Mourits MP, Veen-van Leeuwen L: Retrobulbar pressures measured during surgical decompression of the orbit. Br J Ophthalmol 1996;80:1042–1045.
31 Rundle FF, Wilson CW: Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945;5:177–194.
32 Garrity JA, Terwee CB, Feldon SE, Wiersinga WM: Assessment of disease severity; in Prummel MF (ed): Recent Developments in Graves’ Ophthalmopathy. London, Kluwer Academic Publishers, 2000, pp 39–57.
33 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol 1997;47:9–14.
34 Gorman CA: The measurement of change in Graves’ ophthalmopathy. Thyroid 1998;8:539–543.
35 Anderton LC, Neoh C, Walshaw D, Dickinson AJ: Reproducibility of clinical assessment in thyroid eye disease. Eur Soc Ophthal Plast Reconstr Surg Annu Meet, Paris, 2000, p 107.
36 Gerding MN, Prummel MF, Kalmann R, Koornneef L, Wiersinga WM: The use of colour slides in the assessment of changes in soft-tissue involvement in Graves’ ophthalmopathy. J Endocrinol Invest 1998;21:459–462.
37 Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF: Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol 2000;52:267–271.
38 Martins JRM, Furlanetto RP, Oliveira LM, Mendes A, Passerotti CC, Chiamolera MI, Rocha AJ, Manso PG, Nader HB, Dietrich CP, Maciel RMB: Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy. Clin Endocrinol 2004;60:726–733.
39 Gerding MN, Prummel MF, Wiersinga WM: Assessment of disease activity in Graves’ ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol 2000;52:641–646.
40 Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H, Nishida H: Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 1992;2:299–305.
41 Just M, Kahaly G, Higer HP, Rosler HP, Kutzner J, Beyer J Thelen M: Graves ophthalmopathy: role of MRI imaging in radiation therapy. Radiology 1991;179:187–190.
42 Prummel MF, Gerding MW, Zonneveld FW, Wiersinga WM: The usefulness of quantitative orbital magnetic resonance imaging in Graves’ ophthalmopathy. Clin Endocrinol 2001;54:205–209.
43 Ohnishi T, Noguchi S, Murakami N, Tajiri J, Harao M, Kawamoto H, Hoshi H, Jinnouchi S, Futami S, Nagamachi S, Watanabe K: Extraocular muscles in Graves’ ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 1994;190:857–862.
44 Polito E, Leccisotti A: MRI in Graves orbitopathy: recognition of enlarged muscles and prediction of steroid response. Ophthalmologica 1995;209:182–186.
45 Gerding MN, van der Zant FM, van Royen EA, Koorneef L, Krenning EP, Wiersinga WM, Prummel MF: Octreotide-scintigraphy is a disease-activity parameter in Graves’ ophthalmopathy. Clin Endocrinol 1999;50:373–379.
46 Konuk O, Atasever T, Mehmet U, Ayvaz G, Yetkin I, Cakir N, Arslan M, Hasanreisoglu B: Orbital gallium-67 scintigraphy in Graves’ ophthalmopathy: a disease activity parameter that predicts the therapeutic response to immunosuppressive treatment. Thyroid 2005;15:358–363.
47 Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM: Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy. Clin Endocrinol 2005;62:154–155.
48 Di Maria C, Allen J, Dickinson J, Neoh C, Perros P: Novel thermal imaging analysis technique for detecting inflammation in thyroid eye disease. J Clin Endocrinol Metab 2014;99:4600–4606.
49 Werner SC: Modification of the classification of the eye changes of Graves’ disease. Am J Ophthalmol 1977;83:725–727.
50 Bartalena L, Wiersinga WM, Pinchera A: Graves’ ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004;27:295–301.
51 Mourits MP, Lombardo SHC, van der Sluijs FA, Fenton S: Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 2004;23:161–168.
52 Sleep TJ, Manners RM: Interinstrument variability in Hertel-type exophthalmometers. Ophthal Plast Reconstr Surg 2002;18:254–257.
53 Van den Broek WA: Normal exophthalmometry values: the need for calibrated exophthalmometers. Orbit 2004;23:147–151.
54 Vardizer Y, Berendschot TTJM, Mourits MP: Effect of exophthalmometer design on its accuracy. Ophthal Plast Reconstr Surg 2005;21:427–430.
55 Bahn RS, Gorman CA: Choice of therapy and criteria for assessing treatment outcome in thyroid-associated ophthalmopathy. Endocrinol Metab Clin North Am 1987;16:391–407.
56 Haggerty H, Richardson S., Mitchell KW, Dickinson AJ: A modified method for measuring uniocular fields of fixation: reliability in normal subjects and in patients with Graves’ orbitopathy. Arch Ophthalmol 2005;123:1–7.
57 Mourits MP, Prummel MF, Wiersinga WM, Koornneef L: Measuring eye movements in Graves’ ophthalmopathy. Ophthalmology 1994;101:1341–1346.
58 Steel DHW, Hoh HB, Potts MJ, Harrad RA: Uniocular fields of fixation in thyroid eye disease. Eye 1995;9:348–351.
59 Sullivan TJ, Kraft SP, Burack C, O’Reilly C: A functional scoring method for the field of binocular single vision. Ophthalmology 1992;99:575–581.
60 Fitzsimons R, White J: Functional scoring of the field of binocular single vision. Ophthalmology 1990;97:33–35.
61 Clark RA, Isenburg SJ: The range of ocular movements decreases with ageing. Trans 25th Meet Eur Strabismus Assoc, Jerusalem, 1986.
62 Adams WE, Haggerty H, Coulthard A, Dickinson AJ: Graves ophthalmopathy – predictors of diplopia. Assoc Res Vision Ophthalmol Meet, Ericeira, 2009.
63 Boboridis K, Assi A, Indar A, Bunce C, Tyers AG: Repeatability and reproducibility of upper eyelid measurements. Br J Ophthalmol 2001;85:99–101.
64 Cole HP, Couvillion JT, Fink AJ, Haik BG, Kastl PR: Exophthalmometry: a comparative study of the Naugle and Hertel instruments. Ophthal Plast Reconstr Surg 1997;13:189–194.
65 Lennerstrand G, Tian S, Isberg B, Landau Hogbeck I, Bolzani R, Tallstedt L, Schworm H: Magnetic resonance imaging and ultrasound measurements of extraocular muscles in thyroid-associated ophthalmopathy at different stages of the disease. Acta Ophthalmol Scand 2007;8:192–201.
66 Kalmann R, Mourits MP: Prevalence and management of elevated intraocular pressure in patients with Graves’ orbitopathy. Br J Ophthalmol 1998;82:754–757.
67 Bartalena L, et al: Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273–285.
68 Barrio-Barrio J, Sabater AL, Bonet-Farriol E, Velasquez-Villoria A, Galofre JC: Graves’ ophthalmopathy: VISA versus EUGOGO classification, assessment, and management. J Ophthalmol 2015;2015:249125.
69 Feldon SE, Muramatsu S, Weiner JM: Clinical classification of Graves’ ophthalmopathy. Identification of risk factors for optic neuropathy. Acta Ophthalmol 1984;102:1469–1472.
70 Ohtsuka K, Nakamura Y: Results of transmedialcanthal ethmoidal decompression for severe dysthyroid optic neuropathy. Jpn J Ophthalmol 1999;43:426–432.
71 Henson DB, Chaudry S, Artes PH, Faragher EB, Ansons A: Response variability in the visual field: comparison of optic neuritis, glaucoma, ocular hypertension, and normal eyes. Invest Ophthalmol Vis Sci 2000;41:417–421.
72 Kennerdell JS, Rosenbaum AE, El-Hoshy MH: Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography. Arch Ophthalmol 1981;99:807–809.
73 Suttorp-Schulten MS, Tijssen R, Mourits MP, Apkarian P: Contrast sensitivity function in Graves’ ophthalmopathy and dysthyroid optic neuropathy. Br J Ophthalmol 1993;77:709–712.
74 Kalmann R, Mourits MP: Diabetes mellitus: a risk factor in patients with Graves’ orbitopathy. Br J Ophthalmol 1999;83:463–465.
75 Birchall D, Goodall KL, Noble JL, Jackson A: Graves’ ophthalmopathy: intracranial fat prolapse on CT images as an indicator of optic nerve compression. Radiology 1996;200:123–127.
76 Weis E, Jhamb A, Chan AK, Chui JP, Hurley M, Heran MKS, Rootman J: Quantitative CT predictors of compressive optic neuropathy in patients with thyroid orbitopathy: a volumetric analysis. 2nd Int Symp Graves’ Orbitopathy, Amsterdam, 2009.
77 Nugent RA, Beldin RI, Neigel JM, Rootman J, Robertson WD, Spinelli J, Graeb DA: Graves’ orbitopathy: correlation of CT and clinical findings. Radiology 1990;177:675–682.
78 Goncalves AC, Silva LN., Gebrim EM, Monteiro ML: Predicting dysthyroid optic neuropathy using computed tomography volumetric analyses of orbital structures. Clinics 2012;67:891–896.
79 Dolman PJ, Rootman J: VISA classification for Graves’ orbitopathy. Ophthal Plast Reconstr Surg 2006;22:319–324.
Prof. Dr. med. Christoph Hintschich, FEBO
University Eye Hospital, Ludwig-Maximilian University Munich
Mathildenstrasse 8
DE–80336 Munich (Germany)
